Loading
A phase 2 trial of Prednisone, Abiraterone acetate in prostate cancer, run by Astellas Pharma Global Development, Inc., now recruiting.
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer is a phase 2 interventional study registered as NCT07005154 by Astellas Pharma Global Development, Inc., with 218 participants planned, started 2025-08-19 and due to reach its primary completion in 2032-05-31. Interventions recorded: ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone. Conditions listed: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Astellas, Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/